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Summary  
The progress of four pharmaceuticals (bezafibrate, carbamazepine, clarithromycin and 
ciprofloxacin) is followed through the treatment stages (screened sewage, settled sewage and 
final effluent) of a large urban wastewater treatment plant (WWTP) employing activated sludge 
treatment.  Concentrations at the inlet to the WWTP are generally higher than those predicted 
from consideration of local pharmaceutical consumption and typical excretion data. Percentage 
removal efficiencies are variable (22.5 – 94.3%) with carbamazepine being the most resistant to 
elimination.  
Introduction 
Future global predictions suggest that the number of drugs being dispensed by 2020 will be 4.5 
trillion doses. The prescribed pharmaceuticals find their way to wastewater treatment plants 
(WWTPs) through excretion or disposal of unused or expired drugs and may be present in the 
discharged effluent as conventional treatment processes, consisting of sedimentation and 
biological transformation, are not designed to efficiently remove them. Therefore, an investigation 
into the fate of pharmaceuticals in the wider aquatic environment is warranted. In this paper, a 
carefully developed analytical method is applied to the detection of bezafibrate, carbamazepine, 
clarithromycin and ciprofloxacin as they pass through a WWTP serving a population of 870,000 
and receiving 244,000 m3 of wastewater per day.  
Methods and Materials 
Wastewater samples (7.5 L) were collected at three stages in the treatment process representing 
screened sewage (following gross solids and grit removal), settled sewage (following passage 
through primary settlement tanks) and final treated effluent (following activated sludge treatment 
and final sedimentation). Surface water samples (20 L) were collected from the River Lee (Lee 
navigation channel) at positions representing both up- and down-stream locations relative to the 
WWTP treated effluent discharge point. Pharmaceuticals were removed from the collected water 
samples using solid phase extraction procedures and subsequently analysed by reverse phase 
high performance liquid chromatography - mass spectrometry (LC-MS). Quantification was 
achieved against clean external standard solutions of known concentration prepared by 
dissolving the pharmaceutical compounds in 5 % v/v methanol/water. 
Results and Discussion 
The concentration ranges and mean values of bezafibrate, carbamazepine, ciprofloxacin and 
clarithromycin monitored at the three different defined treatment stages in the  WWTP (together 
with the frequencies of detection) are compared with previously published data in Table 1. There 
is considerable variability in the data, particularly in the most contaminated samples (screened 
and settled sewage) for bezafibrate, carbamazepine and ciprofloxacin but the concentrations are 
compatible with the ranges found in the literature. Bezafibrate and carbamazepine were detected 
on most occasions at all wastewater sampling sites. 
 Table 1. Pharmaceuticals detected in wastewater sampled at different points throughout the 
wastewater treatment process compared with published data. 
 
Scaling down the national data for quantities of pharmaceuticals dispensed nationally in the 
community to the population size located within the WWTP catchment provides estimates of 
influent concentrations of the order of 660, 670, 860 and 560 ng/L for bezafibrate, 
carbamazepine, ciprofloxacin and clarithromycin after taking into account the percentages 
expected to be excreted unchanged. These predicted influent concentrations are towards the 
lower end of the measured ranges (Table 1) which exhibit the expected decreasing trend within 
the wastewater treatment process.  The mean percentage reductions based on the measured 
concentration changes (with standard deviations) achieved during primary sedimentation and 
activated sludge treatment and for the overall wastewater treatment process are shown in Figure 
1. Only small percentage reductions (15-22%) occurred during the primary sedimentation 
process however this noticeably increased in the activated sludge phase for bezafibrate and 
ciprofloxacin leading to high overall removal percentages of 89.7 ± 5.7% and 94.3 ± 0.5%, 
respectively. Conversely, carbamazepine demonstrated only a modest overall removal efficiency 
(22.5 ± 11.9%) as a consequence of a highly variable but negative average removal efficiency (-
4.7 ± 52.9%) for the activated sludge treatment stage. None of the target pharmaceuticals were 
completely removed during the wastewater treatment process. 
 
 
Figure 1. The percentage reductions of bezafibrate, carbamazepine, ciprofloxacin and 
clarithromycin following primary sedimentation, activated sludge treatment and overall treatment. 
 The monitored removal efficiencies of the different pharmaceuticals can be explained by their 
tendencies to sorb to sludge/suspended solids and/or by the extent of their biodegradation by 
micro-organisms. These characteristics are, in turn, dependent on the varying properties of 
pharmaceutical molecules due to their typically large, chemically complex structures, containing 
multiple ionisation sites spread throughout the molecules resulting in wide varieties of physico-
chemical characteristics.  
 The incomplete removal of pharmaceuticals during wastewater treatment processes poses 
problems for receiving waters as evidenced by the down-stream concentrations reported in Table 
2. As contaminants of emerging concern, the impact of pharmaceuticals on receiving waters 
needs to be assessed. The ratio of the predicted or measured surface water pharmaceutical 
concentration to the predicted no-effect concentration defines the hazard quotient and identifies 
an unacceptable environmental risk when values exceed unity. The calculated hazard quotients 
for fish, daphnids and algae (Table 3) indicate that the levels of pharmaceuticals found in both 
the final effluent and in the receiving surface water do not pose a potential ecological impact 
except in the case of clarithromycin in the final effluent when a high risk of causing ecological 
damage to algae is predicted. However, in the presence of multiple pharmaceuticals, which can 
be expected in most aquatic environments, the overall ecological threat can be expected to be 
enhanced. However, comprehensive environmental risk assessments are only required for new 
medicines and so the monitored pharmaceuticals are exempt.  
 
 
 
 Table 2. Pharmaceuticals detected in receiving waters above and below WWTP discharge point 
compared with published data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. The application of PNEC values (a) to calculate hazard quotients for bezafibrate, 
carbamazepine, ciprofloxacin and clarithromycin in the final sewage effluent (b) and in the 
receiving water (c). 
 
 
